


This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

1. (Currently amended) A compound of formula (1):



(1)

wherein:

m and n, which may be the same or different, is are each zero or the integer 1 or 2;

Alk<sup>3</sup> is a covalent bond or a straight or branched C<sub>1-6</sub> alkylene;

R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, is are each a hydrogen atom or a straight or branched C<sub>1-6</sub> alkyl group;

D is an optionally substituted aromatic or heteroaromatic group;

E is an optionally substituted C<sub>7-10</sub> cycloalkyl, C<sub>7-10</sub> cycloalkenyl or C<sub>7-10</sub> polycycloaliphatic group;

and the salts, solvates, hydrates, tautomers or N-oxides thereof.

2. (Currently amended) A compound according to Claim 1 wherein m and n, which may be the same or different, is are each zero or the integer 1.

3. (Currently amended) A compound according to Claim 2 wherein m and n ~~is are~~ each the integer 1.

4. (Currently amended) A compound according to ~~any one of Claims 1-3~~ Claim 1 wherein Alk<sup>3</sup> is a -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- chain.

5. (Original) A compound according to Claim 4 wherein Alk<sup>3</sup> is a -CH<sub>2</sub>- chain.

6. (Currently amended) A compound according to ~~any one of Claims 1—5~~ Claim 1 wherein R<sup>1</sup> and R<sup>2</sup>, which may be the same or different, is are each a hydrogen atom or a methyl group.

7. (Currently amended) A compound according to ~~any one of Claims 1—6~~ Claim 1 wherein D is an optionally substituted phenyl, 1- or 2-naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, quinolinyl, isoquinolinyl, pyrrolyl, furyl, thienyl, imidazolyl, N-C<sub>1-6</sub>alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl group.

8. (Original) A compound according to Claim 7 wherein D is an optionally substituted phenyl, 2-naphthyl or thienyl group.

9. (Currently amended) A compound according to ~~any one of Claims 1—8~~ Claim 1 wherein E is an optionally substituted cycloheptyl, cyclooctyl, cyclononyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]heptenyl, bicyclo[3.1.1]heptanyl or bicyclo[3.3.1]heptenyl group.

10. (Currently amended) A compound according to Claim 9 wherein E is a 1-cyclooctenyl, ~~or~~ 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl, adamantyl or cyclooctyl group.

11. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any of Claims 1 to 10~~ Claim 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.

12. (Cancelled)

13. (New) A method for the treatment of a disease or disorder in a mammal in which inappropriate T-cell trafficking plays a role, comprising administering to said mammal a therapeutically effective amount of a compound according to Claim 1.

14. (New) A method according to Claim 13 wherein said disease or disorder is selected from the group consisting of inflammatory or allergic diseases, autoimmune diseases, graft rejection, and diseases in which undesired inflammatory responses are to be inhibited.

15. (New) A method according to Claim 14 wherein said disease or disorder is an inflammatory or allergic disease.

16. (New) A method according to Claim 15 wherein said inflammatory or allergic disease is selected from the group consisting of systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies, inflammatory bowel diseases, vaginitis, psoriasis and inflammatory dermatoses, vasculitis, spondyloarthropathies, scleroderma, and respiratory allergic diseases.

17. (New) A method according to Claim 14 wherein said disease or disorder is an autoimmune disease.

18. (New) A method according to Claim 17 wherein said autoimmune disease is selected from the group consisting of arthritis, multiple sclerosis, systemic lupus erythematosus, diabetes, and glomerulonephritis.

19. (New) A method according to Claim 14 wherein said disease or disorder is graft rejection.

20. (New) A method according to Claim 14 wherein said disease or disorder is a disease in which an undesired inflammatory response is to be inhibited.

21. (New) A method according to Claim 20 wherein said disease is selected from the group consisting of atherosclerosis, myositis, neurodegenerative diseases, Alzheimer's disease, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, conjunctivitis, otitis,

chronic obstructive pulmonary disease, sinusitis, Behcet's syndrome, Sjorgen's syndrome and glomerulonephrites.

22. (New) A method for inhibiting, in a mammal suspected to suffer from a disease or disorder in which chemokine-mediated cell signaling plays a role, the binding of chemokines to the CXCR3 receptor, comprising administering to the mammal an effective amount of a compound according to Claim 1.